Expired Study
This study is not currently recruiting Study Participants on ClinicalConnection.com. If you would like to find active studies please search for clinical trials.

Novato, California 94949


Purpose:

The purpose of the study is evaluate the efficacy, safety, and pharmacokinetics of weekly intravenous infusions of 1 mg/kg recombinant human N-acetylgalactosamine 4-sulfatase (rhASB) in patients diagnosed with Mucopolysaccharidosis VI (MPS VI)


Criteria:

Inclusion Criteria: - Patient consent - Patient must be five years of age or older - Patient must have documented biochemical or genetic proof of MPS VI - Patient must walk at least 1 meter, but less than 250 meters, in the first 6 minutes of the baseline 12-minute walk test - If female of childbearing potential, patient must have a negative pregnancy test Exclusion Criteria: - Patient is under consideration for or has undergone a successful bone marrow transplant (BMT). - Pregnant or lactating patient - Patient has received an investigational drug within 30 days prior to study enrollment - Patient has been previously treated with rhASB - Patient has a medical condition, serious intercurrent illness, or other extenuating circumstance that may significantly confound study results or decrease study compliance - Patient has a known hypersensitivity to rhASB or to components of the study drug - History of cancer (except low grade and fully resolved skin malignancy)


NCT ID:

NCT00048711


Primary Contact:

Study Director
Stuart J Sweidler, MD, Ph.D.
BioMarin Pharmaceutical


Backup Contact:

N/A


Location Contact:

Novato, California 94949
United States



There is no listed contact information for this specific location.

Site Status: N/A


Data Source: ClinicalTrials.gov

Date Processed: December 16, 2017

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.


Click to view Full Listing

This study is not currently recruiting Study Participants on ClinicalConnection.com. The form below is not enabled.